Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc

Bullboard Posts

Post by FactFinder1994on Nov 30, 2015 4:53pm

175 Views

Post# 24340047

Key Trials and name definitions

See the definitions (medical) for the trial names below EUPHAS Early Use of Polymyxin B Hemoperfusion in Abdominal Septic Shock EUPHRATES Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized control trial of Adults Treated for Endotoxemia and Septic shock The ongoing Euphas 2 Registry will also continue to provide valuable data

Bullboard Posts

How one company is disrupting PoC testing